Sir,

Obsessive-compulsive disorder (OCD) poses significant subjective distress and bio-sociooccupational dysfunction with psychotherapy and selective serotonin reuptake inhibitors (SSRIs) as the first line of treatment. Other common pharmacological options are clomipramine and second-generation antipsychotics. Noninvasive brain stimulation techniques are experimental strategies for OCD.\[[@ref1][@ref2]\] Here, we present a case of resistant OCD, where electroconvulsive therapy (ECT) was the only successful treatment option.

An 18-year-old boy with the significant genetic loading of OCD in the family, presented with illness duration of 6 years, characterized by insidious in onset, continuous and progressive course with predominantly obsessions of contamination, fear and pathological doubts, the compulsion of reassurance seeking, significant anxiety, avoidance, pathological slowness, and compulsion by proxy. He was bedridden most of the time or using a wheelchair for ambulation. OCD substantially affected his personal care such as eating, micturition, defecation, and social functioning. His Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score was 35 at the time of admission. Multiple adequate trials of SSRI (fluoxetine, fluvoxamine, and paroxetine), clomipramine, and augmentation with risperidone had been failed. All baseline investigations were normal. He was started on venlafaxine 300 mg/day. Psychotherapy other than behavioral activation could not be possible due to extreme pathological slowness. Depressive episode and psychosis were ruled out. On family assessment, significant accommodation behavior was found.

In view of symptoms like passing urine and stool on the bed along with poor oral intake and significant pathological slowness, he was started on ECT. After 8 sessions of ECT (3 times a week on alternate days), his Y-BOCS score dropped down to 12. ECT was stopped in view of cognitive deficits. Soon after 5 days, he got worsened with Y-BOCS score 35. Again after re-starting ECT, the Y-BOCS scores dropped down to 16, 6, and 6, respectively, after 2^nd^, 4^th^, and 6^th^ ECT. He did not continue ECT due to logistic issues and worsened again 1 week after stoppage of ECT with Y-BOCS score 35 \[[Figure 1](#F1){ref-type="fig"}\]. Later, the patient was followed up through telepsychiatry where he was found to be significantly worsened even with continuous intake of venlafaxine 300 mg.
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Only 40%--60% of cases of OCD show the response to combination therapy. Next line of treatment in OCD is somatic treatment such as ECT, repetitive transcranial magnetic stimulation, and transcranial direct current stimulation but evidence regarding the effect of ECT are sparse.\[[@ref2]\] A recent systematic review published in 2015 showed that the role of ECT in the routine treatment of OCD is not significant, but it proposed the beneficial effects of ECT in OCD under special circumstances.\[[@ref1]\] Most of the cases who improved on ECT were benign. Furthermore, evidence of the positive responses to ECT were more commonly described in recent studies than the older one.\[[@ref1]\] Here, in our case, the patient was tried with multiple SSRIs and clomipramine but did not show any response where ECT surprisingly benefited the patient by reducing the obsessions and related dysfunctions. Even though ECT has poor evidence as a treatment of OCD, we can consider it in such cases where we do not have any other options to implement. As our patient maintained improvement while on ECT but worsened soon after the stoppage, maintenance therapy of ECT in OCD can be considered in special cases. Maintenance ECT has the potential of preventing implementation of invasive procedure like neurosurgery when OCD becomes refractory to treatment.
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